38.28

0.34% +0.13

After Hours: 38.28

Rhythm Pharmaceuticals Inc. (RYTM)

Overview News Price History Option Chain Discussions Forecast

Rhythm Pharmaceuticals Inc. stock is currently priced at $38.28, with a 24-hour trading volume of 305.05K. It has seen a +0.34% increased in the last 24 hours and a -3.16% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $38.09 pivot point. If it approaches the $38.83 resistance level, significant changes may occur.

Previous Close:

$38.15

Open:

$38.39

24h Volume:

305.05K

Market Cap:

$2.30B

Revenue:

$77.43M

Net Income/Loss:

$-184.68M

P/E Ratio:

-11.67

EPS:

-3.28

Net Cash Flow:

$-136.20M

1W Performance:

+0.71%

1M Performance:

-3.16%

6M Performance:

+63.38%

1Y Performance:

+81.85%

1D Range:

$37.36

$38.89

52W Range:

$15.50

$52.57

Rhythm Pharmaceuticals Inc. Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc.

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

857-264-4280

Address

500 Boylston Street, 11th Floor, Boston, MA

Employee

Twitter

@rhythmpharma

Next Earnings Date

2024-05-14

Latest SEC Filings

RYTM's Discussions on Twitter

Rhythm Pharmaceuticals Inc. Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc. Stock (RYTM) Latest News

Analyst Expectations For Rhythm Pharmaceuticals's Future

Benzinga

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

GlobeNewswire Inc.

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

GlobeNewswire Inc.

Rhythm Pharmaceuticals Inc. Stock (RYTM) Financials Data

Rhythm Pharmaceuticals Inc. (RYTM) Revenue 2024

RYTM reported a revenue (TTM) of $77.43 million for the quarter ending December 31, 2023, a +227.56% rise year-over-year.

Rhythm Pharmaceuticals Inc. (RYTM) Net Income 2024

RYTM net income (TTM) was -$184.68 million for the quarter ending December 31, 2023, a -1.97% decrease year-over-year.

Rhythm Pharmaceuticals Inc. (RYTM) Cash Flow 2024

RYTM recorded a free cash flow (TTM) of -$136.20 million for the quarter ending December 31, 2023, a +23.36% increase year-over-year.

Rhythm Pharmaceuticals Inc. (RYTM) Earnings per Share 2024

RYTM earnings per share (TTM) was -$3.20 for the quarter ending December 31, 2023, a +8.05% growth year-over-year.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.